Atea Pharmaceuticals, Inc. (AVIR) stock
Close on Nov 12, 2026Market cap $337.66MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $337.66M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.92
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$155.40M
- EPS, diluted
- -$1.95
- Book value per share
- $2.19
- Diluted shares
- 80M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $4.22
- Open
- $4.17
- Day's range
- $4.09 – $4.29
- Volume
- 244,197
- Average volume (20 days)
- 305,583
- Index membership
- Russell 2000 (since Dec 2020), Russell 3000 (since May 2025)
- Beta (5 years)
- 0.91
- 52-week range
- $2.87 – $6.45
- RSI (14 days)
- 42.1
- Volatility (1 year)
- 52.4%
- Relative volume
- 0.81×
- WACC
- 9.6%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AVIR | S&P 500 | Difference | AVIR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.3% | -2.7% | −13.6 pts | ||
| 3 months | -16.8% | -1.7% | −15.1 pts | ||
| Year to date | +17.9% | +11.9% | +6.0 pts | ||
| 1 year | +20.3% | +12.0% | +8.3 pts | ||
| 3 years | +45.2% | +78.2% | −33.0 pts | +13.2% | +21.2% |
| 5 years | -62.9% | +73.2% | −136.2 pts | -18.0% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Atea Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Atea Pharmaceuticals
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing orally administered antiviral therapies for serious viral conditions. Utilizing a proprietary nucleos(t)ide platform, it designs candidate treatments targeting single-stranded ribonucleic acid viruses. Its leading pipeline asset is a combination regimen of bemnifosbuvir and ruzasvir, currently evaluated in late-stage clinical trials for treating hepatitis C virus infections across multiple genotypes. Additionally, the business is advancing AT-587, an oral antiviral candidate intended to treat chronic hepatitis E virus infections, specifically targeting immunocompromised patient populations who currently lack approved targeted therapeutic options.
Company profile, executives and historyAtea Pharmaceuticals stock: common questions
What is Atea Pharmaceuticals's stock price?
AVIR closed at $4.21 on Nov 12, 2026, down 0.24% on the day. Over the past 52 weeks it traded between $2.87 and $6.45.
What is Atea Pharmaceuticals's market cap?
Atea Pharmaceuticals was worth $337.66M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AVIR's P/E ratio?
Atea Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.95), so it has no meaningful P/E ratio.
Does Atea Pharmaceuticals pay a dividend?
No. Atea Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Atea Pharmaceuticals report earnings next?
Atea Pharmaceuticals is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has AVIR stock performed over the past year?
Including dividends, AVIR returned +20.3% over the past year, against +12.0% for the S&P 500.
How many AVIR shares are sold short?
3M shares were sold short at the latest FINRA report, 4.60% of the float, or 9.6 days of average trading volume.
Who are Atea Pharmaceuticals's competitors?
Companies most similar to Atea Pharmaceuticals by business, industry and size include ASMB, COCP, NAMS, ALNY, ENTA.
See a number that looks wrong?